Weight maintenance on cost‐effective antiobesity medications after 1 year of GLP‐1 receptor agonist therapy: a real‐world study

🎖️ Top 10% JournalNov 19, 2024Obesity (Silver Spring, Md.)

Keeping weight off with affordable anti-obesity medicines after 1 year of GLP-1 treatment in real life

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

At 12 months, patients who transitioned to generic lost an average of 18.3% of their body weight from baseline.

Patients had a mean baseline BMI of 36.4 kg/m.
After transitioning to generic antiobesity medications, patients maintained a mean BMI of 27.9 kg/m at 12 and 18 months.
Further follow-up indicated a total average weight loss of 25.5% compared to the initial visit.
The findings suggest that older-generation antiobesity medications may effectively support weight maintenance after initial weight loss with .

AI simplified

OBJECTIVE: The high cost of novel glucagon-like peptide-1 receptor agonist (GLP-1 RA) class agents often limits access and creates barriers to care. This real-world study evaluated the efficacy of older-generation generic (AOMs) for weight maintenance after 1 year of GLP-1 RA therapy in patients who had achieved successful weight loss.

METHODS: We prospectively followed patients (N = 105) who had completed 12 months of therapy and were part of a "medical weight loss bundle," which included 12 months of GLP-1 RA therapy followed by 6 months of transition care. The baseline mean BMI was 36.4 kg/m. Body weight outcomes were measured at 6, 12, 18, and 24 months. 2

RESULTS: After the medical weight loss bundle, 40 patients transitioned to generic AOMs. At 12 months, this cohort lost an average of 18.3%, 95% CI [13.0%, 23.6%] body weight from baseline, with a mean BMI of 27.9 kg/m. At 18 months, they maintained the weight loss, with a mean BMI of 27.9 kg/m. Subsequent follow-up visits (average 1.5 months later) without GLP-1 RAs showed further reduction, resulting in a total average weight loss of 25.5%, 95% CI [23.1%, 27.9%] compared to the initial visit. 2 2

CONCLUSIONS: Patients successfully treated with GLP-1 RAs can maintain their weight loss using generic older-generation AOMs, suggesting potential cost savings for insurers and implications for policy regarding AOM coverage.

Key numbers

18.3%

Average Weight Loss at 12 Months

Percentage weight loss from baseline after 12 months on .

25.5%

Total Average Weight Loss

Percentage weight loss compared to initial visit after 18 months.

27.9 kg/m²

Mean BMI at 18 Months

Mean body mass index of patients at 18 months post-transition.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text ↗

Abstract

Key numbers

Full Text

Related papers